New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2014
08:11 EDTALKSAlkermes aripiprazole lauroxil data looks good, says Leerink
Leerink says the data Alkermes presented from its Phase III trial of aripiprazole lauroxil for treatment of schizophrenia at the American Society of Clinical Psychopharmacology Annual Meeting looks good. The firm expects FDA approval of AL in Q3 of 2015 following a 12-month regulatory review. It maintains an Outperform rating on the stock with a $66 price target.
News For ALKS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 18, 2015
07:43 EDTALKSJefferies to hold a conference
Subscribe for More Information
November 16, 2015
08:12 EDTALKSLeerink reiterates Outperform rating, $84 target on Alkermes
After hosting a conference call with CEO Richard Pops and CFO Jim Frates, Leerink analyst Paul Matteis reiterates an Outperform rating on Alkermes with an $84 price target. The analyst continues to believe the '5461 FORWARD Phase 3 program for depression is "employing a robust, proven study design." The drug likely only needs to hit on two of three pivotal efficacy studies for FDA approval, Matteis reiterates to investors in a research note.
07:57 EDTALKSLeerink biotech analyst holds an analyst/industry conference call
Biotech Analyst Matteis, along with MEDACorp specialists Anthony Rothschild, M.D., Director of the University of Massachusetts Depression Center and Darin Dougherty, M.D., Harvard Medical School, discuss their views on Alkermes' ALKS-5461's probability-of-success in Phase III and the commercial potential of ALKS-5461 on an Analyst/Industry conference call to be held on November 16 at 2 pm.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use